CN115697415A - 用于预防或治疗感染的技术 - Google Patents

用于预防或治疗感染的技术 Download PDF

Info

Publication number
CN115697415A
CN115697415A CN202180035832.5A CN202180035832A CN115697415A CN 115697415 A CN115697415 A CN 115697415A CN 202180035832 A CN202180035832 A CN 202180035832A CN 115697415 A CN115697415 A CN 115697415A
Authority
CN
China
Prior art keywords
xaa
medicament
independently
amino acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035832.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·S·拜登
T·贝尔巴索娃
L·E·费希尔
W·卡兹米尔斯基
L·拉斯泰利
T·K·索耶
D·A·斯皮格尔
W·C·维迪森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Pharmaceutical Holding Co Ltd
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of CN115697415A publication Critical patent/CN115697415A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180035832.5A 2020-03-25 2021-03-25 用于预防或治疗感染的技术 Pending CN115697415A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062994779P 2020-03-25 2020-03-25
US62/994,779 2020-03-25
US202063001455P 2020-03-29 2020-03-29
US63/001,455 2020-03-29
US202063055860P 2020-07-23 2020-07-23
US63/055,860 2020-07-23
PCT/US2021/024186 WO2021195401A1 (en) 2020-03-25 2021-03-25 Technologies for preventing or treating infections

Publications (1)

Publication Number Publication Date
CN115697415A true CN115697415A (zh) 2023-02-03

Family

ID=77890439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035832.5A Pending CN115697415A (zh) 2020-03-25 2021-03-25 用于预防或治疗感染的技术

Country Status (12)

Country Link
US (1) US20230330240A1 (https=)
EP (1) EP4125893A4 (https=)
JP (1) JP2023520188A (https=)
KR (1) KR20220158762A (https=)
CN (1) CN115697415A (https=)
AU (1) AU2021244228A1 (https=)
BR (1) BR112022018945A2 (https=)
CA (1) CA3176256A1 (https=)
IL (1) IL296725A (https=)
MX (1) MX2022011692A (https=)
PH (1) PH12022552499A1 (https=)
WO (1) WO2021195401A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
CN116440285A (zh) * 2023-04-19 2023-07-18 山西锦波生物医药股份有限公司 冠状病毒多肽类融合抑制剂的长效化的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023501A1 (en) * 2017-07-26 2019-01-31 Kleo Pharmaceuticals, Inc. UNIVERSAL ABT COMPOUNDS AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023501A1 (en) * 2017-07-26 2019-01-31 Kleo Pharmaceuticals, Inc. UNIVERSAL ABT COMPOUNDS AND USES THEREOF

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVIDY.JACKSON: "ProcessesforConstructingHomogeneousAntibodyDrug Conjugates", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》, vol. 20, 14 April 2016 (2016-04-14), pages 852 - 866 *
LILI WANG等: "Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV", 《ANTIBODIES (BASEL)》, vol. 8, 4 November 2019 (2019-11-04), pages 1 - 11 *
SCHLEIFER KH等: "The immunochemistry of peptidoglycan. Antibodies against a synthetic immunogen cross-reacting with peptidoglycan", 《EUROPEAN JOURNAL OF BIOCHEMISTRY》, vol. 43, 31 December 1974 (1974-12-31), pages 509 - 519, XP000566952, DOI: 10.1111/j.1432-1033.1974.tb03438.x *
ZHE YAN等: "Design and Study of Novel Peptide Inhibitors against the SARS-Coronavirus Spike Protein", 《UNDERSTANDING BIOLOGY USING PEPTIDES》, 31 December 2005 (2005-12-31), pages 335 - 337 *

Also Published As

Publication number Publication date
US20230330240A1 (en) 2023-10-19
MX2022011692A (es) 2023-02-09
BR112022018945A2 (pt) 2022-12-13
JP2023520188A (ja) 2023-05-16
CA3176256A1 (en) 2021-09-30
EP4125893A4 (en) 2024-10-16
EP4125893A1 (en) 2023-02-08
KR20220158762A (ko) 2022-12-01
PH12022552499A1 (en) 2024-03-25
IL296725A (en) 2022-11-01
AU2021244228A1 (en) 2022-11-17
WO2021195401A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
JP2023501720A (ja) 指向性コンジュゲーション技術
JP2019510810A (ja) インドールアミン−２，３−ジオキシゲナーゼ（ｉｄｏ）阻害剤
AU2009268349C1 (en) Glycopeptide constructs and uses thereof
CN103108654A (zh) 多价糖肽构建体及其用途
CN115697415A (zh) 用于预防或治疗感染的技术
CN116323638A (zh) 订书钉化肽及其方法
KR20240031957A (ko) 스테이플화된 펩티드 및 이의 방법
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
CN114401732A (zh) Cd38结合剂和其用途
JP2024521092A (ja) 細胞傷害性薬剤を送達するためのｍａｔｅｓ技術を使用する抗体薬物コンジュゲート
WO2019222349A1 (en) Compounds for treating dengue virus infections and other infections
WO2022170155A2 (en) Technologies for preventing or treating infections
JP2025541247A (ja) ステープルペプチドおよびその方法
JP2025541246A (ja) ステープルペプチドおよびその方法
HK40129655A (zh) 订书钉化肽及其方法
HK40128981A (zh) 订书钉化肽及其方法
KR20230169230A (ko) 시클릭 펩티드 면역조정제
HK40108355A (zh) 订书钉化肽及其方法
KR20230084209A (ko) 이량체 밀라 면역조정제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination